Adjuvant nivolumab for resected high-risk head and neck cancer

The Lancet 2026

View at publisher

Authors: Annette May Ling Lim, Danny Rischin

DOI: 10.1016/s0140-6736(26)00133-9

Cited by: 1

References: 12

Fields of Study & Subjects

Head and Neck Cancer Studies Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses

References 12